{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:31:03Z","timestamp":1775064663269,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.nucmedbio.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T03:19:36Z","timestamp":1366687176000},"page":"630-637","source":"Crossref","is-referenced-by-count":22,"title":["Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments"],"prefix":"10.1016","volume":"40","author":[{"given":"Claire M.B.","family":"Holloway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Scollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis B.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriette J.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1075-122X.2004.21323.x","article-title":"Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study","volume":"10","author":"Engel","year":"2004","journal-title":"Breast J"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0002-9610(02)01012-7","article-title":"Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy","volume":"184","author":"Singletary","year":"2002","journal-title":"Am J Surg"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3816\/CBC.2005.n.001","article-title":"Predictors of local recurrence after breast-conservation therapy","volume":"5","author":"Horst","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/cncr.20153","article-title":"Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma","volume":"100","author":"Leong","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0360-3016(03)00740-5","article-title":"Predictors of reexcision findings and recurrence after breast conservation","volume":"57","author":"Smitt","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0360-3016(00)01378-X","article-title":"True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management","volume":"48","author":"Smith","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jnci\/92.4.313","article-title":"Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences","volume":"92","author":"Waldman","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0045","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1998.16.2.441","article-title":"Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0055","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0360-3016(89)90061-8","article-title":"Late cosmetic outcome after conservative surgery and radiotherapy: analysis of causes of cosmetic failure","volume":"17","author":"Olivotto","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0060","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.0.CO;2-7","article-title":"Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis","volume":"85","author":"Boyages","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(97)82498-4","article-title":"The value of breast lumpectomy margin assessment as a predictor of residual tumor burden","volume":"38","author":"Wazer","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jso.20059","article-title":"Positive margins following surgical resection of breast carcinoma: analysis of pathologic correlates","volume":"86","author":"Miller","year":"2004","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0075","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1245\/ASO.2004.12.037","article-title":"Factors associated with residual breast cancer after re-excision for close or positive margins","volume":"11","author":"Cellini","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0080","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s002689900510","article-title":"Excising the reexcision: stereotactic core-needle biopsy decreases need for reexcision of breast cancer","volume":"22","author":"Kaufman","year":"1998","journal-title":"World J Surg"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1006\/jsre.1998.5380","article-title":"Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer","volume":"78","author":"Lind","year":"1998","journal-title":"J Surg Res"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0090","article-title":"Trends in advanced imaging use for women undergoing breast cancer surgery","author":"Breslin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jncimonographs\/lgq037","article-title":"Imaging for the diagnosis and management of ductal carcinoma in situ","volume":"2010","author":"D'Orsi","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0100","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0046-8177(92)90257-4","article-title":"Overexpression of HER-2\/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer","volume":"23","author":"Allred","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.nucmedbio.2010.06.010","article-title":"A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER-2 positive breast cancer","volume":"38","author":"Scollard","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0115","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nucmedbio.2004.08.003","article-title":"Imaging of HER2\/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments","volume":"32","author":"Tang","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0125","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s002590050288","article-title":"Evaluation of surgical gamma probes for radioguided sentinel node localisation","volume":"25","author":"Tiourina","year":"1998","journal-title":"Eur J Nucl Med"},{"issue":"1 Suppl","key":"10.1016\/j.nucmedbio.2013.03.005_bb0130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cncr.2820741321","article-title":"Overview of the biology and management of ductal carcinoma in situ of the breast","volume":"74","author":"Frykberg","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0135","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.2005.03.8448","article-title":"Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"24","author":"Perik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0140","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJM200109273451312","article-title":"Trastuzumab and breast cancer","volume":"345","author":"Behr","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0145","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0150","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","article-title":"Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer\u2014results from the GeparQuattro study (GBG 40)","volume":"132","author":"von Minckwitz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.remn.2011.02.008","article-title":"Effective doses associated to the usual multimodal examinations in nuclear medicine","volume":"30","author":"Camacho L\u00f3pez","year":"2011","journal-title":"Rev Esp Med Nucl"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0160","first-page":"545034","article-title":"Feasibility evaluation of radioimmunoguided surgery of breast cancer","author":"Ravi","year":"2012","journal-title":"Int J Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2013.03.005_bb0165","first-page":"37","article-title":"Probe-guided localization of cancer deposits using [18F]fluorodeoxyglucose","volume":"52","author":"Piert","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511300053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511300053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T16:26:34Z","timestamp":1539707194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511300053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S096980511300053X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.03.005","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}